Simple answers first, with evidence, safety and source links when you want to go deeper.
The public knowledge base currently includes 97 source-reviewed pages across peptides, access and safety, longevity drugs, NAD, biological age, gene therapy, senolytics and basics. High-risk pages keep the no-protocol boundary visible.
The most useful pages for readers arriving from search, social or AI answers.
Profile
BPC-157 is widely discussed because animal and mechanism studies make tissue-repair claims sound plausible, but strong human proof for gym injuries o...
Question
BPC-157 is a synthetic peptide promoted online for injury repair, gut health and recovery.
Safety guide
People may encounter BPC-157 through clinic or telehealth offers, compounding claims, international clinics, clinical-trial discussions, social media...
Profile
TB-500 is not proven to speed injury recovery in people.
Guide
A peptide is a short chain of amino acids.
Guide
Some longevity-drug candidates are real, approved medicines.
Guide
NAD biology matters, and some precursors can affect NAD-related measures.
Guide
Biological age is an estimate of aging-related state, not a literal countdown.
Guide
A peptide is a short chain of amino acids.
Guide
Some longevity-drug candidates are real, approved medicines.
Guide
NAD biology matters, and some precursors can affect NAD-related measures. But raising a biomarker is not the same as proving slower aging, longer lifespan or meaningful healthspan benefit.
Guide
Biological age is an estimate of aging-related state, not a literal countdown. Some measures are useful; others are exploratory. The danger is treating one score as proof that a protocol works.
Guide
Gene therapy is real medicine for specific diseases, but consumer anti-aging gene therapy is a different and much more speculative claim. Frontier does not mean available or proven.
Guide
Senolytics target senescent cells, a real aging-biology area. But real biology does not mean people should run DIY senolytic protocols. Human evidence, selectivity, timing and safety remain central.
Guide
The strongest longevity basics are not exotic: do not smoke, maintain cardiovascular and metabolic health, build fitness and strength, sleep enough, preserve muscle and manage risk factors with qualified care.
Profile
BPC-157 is widely discussed because animal and mechanism studies make tissue-repair claims sound plausible, but strong human proof for gym injuries or anti-aging is still missing.
Profile
TB-500 is not proven to speed injury recovery in people.
Profile
Thymosin beta-4 biology helps explain why wound-healing claims attract attention, but it is not the same as proving TB-500 recovery products work in consumers.
Safety guide
There is no universal safe way to take BPC-157 that this page can give.
Safety guide
People may encounter BPC-157 through clinic or telehealth offers, compounding claims, international clinics, clinical-trial discussions, social media or research-chemical sellers.
Safety guide
There is no single category of doctor whose role is to prescribe BPC-157 for anti-aging or gym recovery.
Safety guide
There is no universal safe method this page can provide.
Safety guide
People may encounter TB-500 through clinic menus, social media, research-chemical sellers or international offers.
Safety guide
Peptide therapy can mean an approved peptide medicine, an off-label medical use, a compounded product, a clinical-trial intervention or a clinic-marketed wellness service.
Safety guide
A research peptide is marketed for laboratory or research use, not as an approved human medicine. If a product is labeled for research only but promoted for human use, that is a major red flag.
Safety guide
'For research use only' means the product is not being sold as an approved medicine for human treatment. It does not tell you the product is safe, lawful to use as a medicine or appropriate for self-experimentation.
Safety guide
People encounter peptides through approved medicines, lawful prescriptions, compounding claims, clinical trials, clinics, telehealth, international offers, social media and research-chemical sellers.
Safety guide
There is no single kind of doctor that safely covers every peptide claim.
Safety guide
Ask what exact product, indication, evidence, approval status, pharmacy, monitoring plan, alternatives and adverse-event process are involved. A responsible clinician should be able to answer without relying on hype.
Safety guide
Red flags include miracle recovery claims, no clear approved use, research-use labels aimed at consumers, pressure to buy bundles, no adverse-event discussion, no pharmacy transparency and claims of FDA approval for ant...
Safety guide
LHN does not provide stack advice because combining peptides, drugs and supplements multiplies uncertainty.
Safety guide
Ask what indication is being considered, what human evidence applies, what risks and monitoring matter, what alternatives exist and what would count as benefit or harm. Do not use an article as a medication plan.
Question
BPC-157 is a synthetic peptide promoted online for injury repair, gut health and recovery.
Question
In research settings, BPC-157 is discussed around tissue-repair, inflammation, blood-vessel and pain-related biology.
Question
No.
Question
There is no useful one-word legal answer for BPC-157.
Question
The biggest BPC-157 risk is not just a known side-effect list.
Question
BPC-157 has been discussed in gastrointestinal research contexts, which helps explain why gut-health claims spread online.
Question
BPC-157 tendon and ligament claims are plausible enough to attract research interest but not proven enough for a consumer treatment claim. The gap is controlled human injury evidence, product quality and approval status.
Question
BPC-157 and TB-500 are often grouped together because both are marketed for recovery.
Question
BPC-157 may be encountered as a research chemical, a clinic offer or a compounding claim.
Question
Athletes should treat BPC-157 as high-risk. USADA frames it as prohibited under WADA's S0 unapproved-substances category. Even outside sport, the evidence and product-quality questions remain unresolved.
Question
BPC-157 went viral because it sits at the intersection of frustrating injuries, plausible repair biology, influencer stories, clinic menus and grey-market access.
Question
TB-500 is a peptide name used in recovery marketing and often linked to thymosin beta-4 biology. The key caution is that related biology does not prove a consumer TB-500 product speeds injury recovery.
Question
Thymosin beta-4 is a naturally occurring molecule involved in actin and repair biology. TB-500 claims often borrow from that biology, but the two should not be treated as identical proof for consumer recovery products.
Question
Not exactly.
Question
People point to repair and wound-healing biology around thymosin beta-4 when discussing TB-500. That is a reason to study the claim, not proof that TB-500 speeds recovery in consumers.
Question
TB-500 is not FDA-approved for broad injury recovery, anti-aging or performance use. Wound-healing biology and compounding discussions should not be read as consumer approval.
Question
TB-500 legal status cannot be reduced to a simple yes.
Question
For TB-500, the risk story is not just a side-effect checklist. It includes limited human evidence, unclear product identity, sterility and quality concerns, anti-doping risk and medical-supervision gaps.
Question
TB-500 injury-recovery claims are not backed by strong human evidence. Related wound-healing biology is interesting, but it is not a consumer recovery verdict.
Question
No. A wound-healing regulatory question is not the same as broad recovery, performance or anti-aging approval. Internet claims often widen the use beyond what a regulator or study is actually considering.
Question
People believe TB-500 recovery claims because repair biology, athlete anecdotes and clinic marketing reinforce each other. That can make a claim feel proven before controlled human evidence exists.
Question
Yes. Route matters for absorption, quality, sterility, supervision and risk. But route differences do not make a weak claim strong. The key is the exact product, indication and human evidence.
Question
Social media can make peptide use look more common and cleaner than it is.
Question
A research chemical, compounded medication and clinic service are different things. None of those labels automatically proves a product is approved, appropriate, effective or safe for a longevity claim.
Question
Doctors worry about DIY peptide injections because uncertainty stacks up: product identity, sterility, adverse effects, interactions, legality, monitoring and false confidence from anecdotes.
Question
Rapamycin, also known as sirolimus, is a real medicine approved for specific uses and a serious geroscience candidate. It is not approved as a human anti-aging drug.
Question
Rapamycin is discussed because mTOR biology and animal lifespan findings are unusually important in aging science. The unresolved part is whether that translates into meaningful, safe human longevity benefit.
Question
PEARL adds useful human data on rapamycin safety and selected healthspan metrics after one year. It does not prove lifespan extension or make rapamycin an approved anti-aging drug.
Question
Rapamycin affects immune and metabolic pathways and is a real prescription drug, not a supplement. Any off-label longevity discussion belongs with qualified medical supervision and clear monitoring.
Question
Rapamycin can be an approved drug and still be off-label for longevity. Approval follows a product, population and indication; it does not automatically transfer to aging claims.
Question
Metformin is a widely used diabetes drug and a serious geroscience candidate. It is not proven to extend lifespan in healthy non-diabetic adults.
Question
Metformin is familiar and widely used, but it is still a drug with contraindications, interaction and monitoring questions. Healthy-adult longevity use is not a proven default.
Question
Metformin and rapamycin are both discussed in geroscience, but they are not interchangeable.
Question
NMN and NR are both NAD precursor strategies. The useful question is not which acronym wins marketing, but which product, dose form, endpoint and human evidence apply. Neither is proven to slow human aging.
Question
Some human evidence suggests specific NMN formulations can raise circulating NAD-related measures. That is a biomarker answer, not proof of slower aging.
Question
NR has human-study interest as an NAD precursor, but raising NAD-related markers does not automatically prove longevity benefit.
Question
NAD IV drip claims often turn real NAD biology into a stronger clinic-service promise. Direct evidence for anti-aging outcomes is not strong enough for age-reversal claims.
Question
A biomarker can be useful without being destiny. Changing a marker does not prove a person will live longer unless that marker is validated for the exact decision and outcome.
Question
Chronological age is how long you have been alive. Biological age is an estimate from biomarkers or models. Biological age can be useful, but it is not a precise personal lifespan forecast.
Question
DunedinPACE is a DNA-methylation based attempt to estimate pace of aging. It may be useful as a research and risk marker, but it should not be overread as proof a specific intervention is working.
Question
No test can tell you exactly how long you will live. Some biological-age measures are associated with risk in groups, but individual prediction and actionability are more limited.
Question
A biological-age score may move, but that does not necessarily mean aging has been reversed. Measurement noise, model choice and short-term physiology can all affect results.
Question
Beginners usually get more value from clinically grounded markers such as blood pressure, ApoB, glucose-related markers, fitness, body composition, smoking status and sleep than from exotic single-number age scores.
Question
VO2 max is a measure of cardiorespiratory fitness and is strongly relevant to longevity discussions. It is not a hack; it is a marker and training target linked to broad health capacity.
Question
Stem-cell and exosome claims are often marketed as regeneration, but product, indication, regulation and evidence vary widely. Frontier language should not be mistaken for approved longevity medicine.
Question
Fisetin is discussed as a senolytic, but robust proof that it clears senescent cells in humans and improves meaningful outcomes is not established.
Question
Dasatinib plus quercetin is a research senolytic combination, not a self-directed longevity routine. Dasatinib is a prescription drug with serious risks.
Question
Before experimental interventions, the best-supported longevity work is usually cardiometabolic risk management, exercise, strength, sleep, nutrition, smoking avoidance and evidence-based medical prevention.
Question
Exercise is one of the most evidence-backed longevity levers. It supports cardiorespiratory fitness, strength, metabolic health, function and resilience.
Question
Zone 2 training can be a useful way to build aerobic capacity, but the longevity target is broader cardiorespiratory fitness and consistency, not worshiping one zone.
Mechanism
mTOR is a nutrient-sensing pathway involved in growth, repair and metabolism. Rapamycin affects mTOR, which explains why aging researchers care, but pathway logic alone does not prove human lifespan benefit.
Mechanism
NAD is a molecule involved in energy metabolism and repair pathways. It is biologically important, but that does not make every NAD supplement or infusion claim true.
Mechanism
An epigenetic clock estimates aging-related patterns from DNA methylation. It can be useful in research and risk prediction, but one test should not be treated as a full medical decision system.
Mechanism
Gene therapy changes or delivers genetic material to treat a specific disease or biological target. Approved gene therapies are evaluated for defined products and uses, not broad anti-aging.
Mechanism
Partial reprogramming aims to shift cells toward a younger-like state without fully erasing their identity. It is scientifically important and still experimental for human aging claims.
Mechanism
OSK refers to three reprogramming factors: Oct4, Sox2 and Klf4. They are part of frontier cellular-reprogramming research, not a consumer anti-aging protocol.
Mechanism
CRISPR is a gene-editing technology. It has serious medical uses and research potential, but CRISPR headlines should not be translated into consumer age-reversal claims.
Mechanism
Telomerase is tied to telomere biology, but turning that into therapy raises major cancer-risk and delivery questions. Telomere claims should not be read as simple age reversal.
Mechanism
Senescent cells have stopped dividing and can release inflammatory signals. They can be harmful in some contexts and useful in others, such as wound healing and cancer suppression.
Mechanism
Senolytics are proposed interventions that selectively remove some senescent cells. The idea is serious, but human translation is still being worked out.
Mechanism
Autophagy is a cellular recycling process. It matters in aging biology, but claims that a product or habit 'boosts autophagy' still need evidence for real outcomes.
Mechanism
AMPK is an energy-sensing pathway involved in metabolism. It helps explain interest in exercise, metformin and fasting claims, but pathway activation is not automatically a health outcome.
Regulatory guide
Some peptide medicines are legal, approved products for specific uses.
Regulatory guide
No. FDA states that compounded drugs are not FDA-approved. A compounded peptide may be prepared in a regulated context, but that does not mean FDA has reviewed that product for safety, effectiveness or quality.
Regulatory guide
A compounding pharmacy prepares medication for a specific patient need when an FDA-approved product is not medically appropriate. That can be legitimate in some contexts, but compounded drugs are not FDA-approved.
Regulatory guide
FDA-approved drug manufacturers make products reviewed for safety, effectiveness and quality for a labeled use.
Regulatory guide
In compounding discussions, Category 2 generally points to bulk substances that may present significant safety risks. This should make a reader more cautious, not more confident that a peptide is approved for anti-aging.
Regulatory guide
The 503A bulk-substances framework is about when certain bulk substances may be used in compounding under federal law. It is not a consumer stamp of approval for anti-aging or recovery claims.
Regulatory guide
The July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee peptide event should be read as a regulatory and compounding-review event, not FDA approval for anti-aging, fitness, recovery or OTC use.
Regulatory guide
A regulator might review one substance for one narrow use while the internet talks about a different use entirely.
Regulatory guide
Athletes need anti-doping context before touching peptide claims. A substance can be unapproved, risky, poorly evidenced and prohibited even if influencers discuss it casually.
Regulatory guide
Approved gene therapies treat specific serious diseases with defined products.
Evidence review
With peptides, the claim is not only whether the molecule could work.
One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.
No protocols. No miracle claims. No spam.